Adverse events during clinical trial. by Nam Kyu Lim (13250298)

“…However, there was no significant difference (<i>p</i> = 0.070). And analysis of epidermal thickness showed a significant increase in LED (495.62 ± 327.09 μm) compared to Sham (195.36 ± 263.04 μm) (<i>p</i> < 0.0001).…”

Feature importance of the extracted characteristics from the simulation using Mean Decrease in Impurity (MDI). by Simon Bin Akter (17951860)

Measures of early life adversity. by Diamantis Toutountzidis (12975607)

Subjects:

<i>neurod1</i>^<i>ΔUCE</i> homozygous mutants display a decrease in the expression of several EE hormones. by Anne Sophie Reuter (12239993)

Survivorship of zebrafish embryos decreased and malformations increased across all treatment time periods as PCP concentrations increased. by Aleeza Namit (12295157)

Subjects:

Geometric mean anti-<i>Na</i>-GST-1 IgG subclass levels over time. by David J. Diemert (8135568)

Subjects:

Mean scores, standard deviations, and significance on key measures and subscales by gender group. by Silas Manning (22693338)

Machine Learning Model Performance Sorted by Decreasing MAE. by Renan N. D. Almeida (9265283)

Significant decrease of the viability of A375 melanoma cells after CD treatment. by Lena Berning (7430117)

Comparing demographic data (mean values). by Tamer Shousha (10960632)

Subjects:

Summary of adverse events. by Hai Huang (140371)

Subjects:

Overview of pipeline steps and study design. by Alireza Talesh Jafadideh (14227404)

HtrA-deficient GBS is associated with fewer adverse pregnancy outcomes despite increased dissemination to fetal tissues. by Alyssa Brokaw (16469975)

Subjects:

Schematic of the multi-Step model. by Anshul Saini (11320669)

The incidence rate of adverse events. by Lipeng Shi (11307700)

Subjects:

Association between GWG and adverse neonatal outcomes in parity subpopulations. by Feifei Jiang (11795243)

Subjects:

Filarial antigens increase post-treatment in individuals with moderate adverse events (AEs). by Britt J. Andersen (5309966)

“…<p>Circulating filarial antigen (CFA) levels increased significantly more post-treatment in individuals who experienced moderate adverse events (mod AEs) compared to individuals with no AEs (<i>P</i> < 0.05 by Kruskal-Wallis) (n = 62 with no AEs, n = 24 with mild AEs, n = 9 with moderate AEs). …”

No adverse effects after STX-S administration. by Mafalda Cacciottolo (16865905)

Intensity of mobilizations and adverse events. by Larissa Faria Borges (6571490)

Subjects:

Outcome measures on step 5. by Timmion K. Skervin (11432568)